Medical - Devices · NYSE
当前价格
$108.03
内在价值
使用下方计算器估算
对 Abbott Laboratories 运行完整的 DCF 分析，自动填充基本面数据，可调节假设参数，含敏感性热力图。
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
ROIC (TTM)
8.4%
ROE (TTM)
12.9%
FCF Yield
3.94%
基于过去 12 个月的数据，ABT 每股自由现金流为 N/A，投入资本回报率（ROIC）为 8.4%，这些是使用 DCF 方法进行股票估值的关键输入。P/FCF 比率为 N/A，FCF 收益率为 3.94%，是评估 ABT 相对估值的重要参考指标。
ABT 的内在价值取决于对未来增长率、折现率（WACC）和终值的假设。使用 MiniValuator 免费 DCF 计算器，输入你自己的假设进行估算，并查看敏感性分析热力图。
ABT 是否被低估取决于你的 DCF 假设。如果计算出的内在价值显著高于当前市价，则可能被低估。安全边际指示低估程度。在 MiniValuator 上运行完整估值来了解。
你可以使用 MiniValuator 的 DCF 计算器对 ABT 估值：输入代码，查看自动填充的基本面数据，调整增长率和折现率假设，即可获得含敏感性热力图的即时内在价值。
DCF（折现现金流）估值通过将公司未来预期自由现金流折现回现值来估算内在价值。对于 ABT，你输入预期增长率和折现率（WACC），模型会根据其未来现金产生能力计算股票当前应有的价值。
WACC（加权平均资本成本）是 ABT 估值中使用的折现率。较高的 WACC 会降低内在价值估算，较低的 WACC 则会提高。使用 MiniValuator 的敏感性热力图查看不同 WACC 假设对 ABT DCF 估值结果的影响。
